SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Am Fam Physician · 2021

Last updated 2026-05-28

Journal	Am Fam Physician, 2021
Citations	0
Relative citation ratio	0.00
NIH percentile	0
Molecules	—
Conditions studied	Type 2 Diabetes, Cardiovascular Risk Reduction

Full record and abstract on PubMed 34383432 ↗